| 84.86 0.87 (1.04%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 101.55  |
1-year : | 118.61 |
| Resists | First : | 86.94 |
Second : | 101.55 |
| Pivot price | 76.91 |
|||
| Supports | First : | 72.82 |
Second : | 64.09 |
| MAs | MA(5) : | 82.75 |
MA(20) : | 75.81 |
| MA(100) : | 58.34 |
MA(250) : | 42.81 |
|
| MACD | MACD : | 3.9 |
Signal : | 3.2 |
| %K %D | K(14,3) : | 94.9  |
D(3) : | 96.6 |
| RSI | RSI(14): 68.9 |
|||
| 52-week | High : | 86.94 | Low : | 7.98 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ NKTR ] has closed below upper band by 12.7%. Bollinger Bands are 19.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 87 - 87.26 | 87.26 - 87.55 |
| Low: | 83.49 - 83.8 | 83.8 - 84.15 |
| Close: | 84.31 - 84.78 | 84.78 - 85.31 |
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Fri, 17 Apr 2026
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics - GlobeNewswire
Fri, 17 Apr 2026
Bright Outlook for Nektar Therapeutics (NKTR) Hinges on Positive Trial Results - Yahoo Finance
Fri, 17 Apr 2026
Two Seas Capital (NKTR) reports 1.96M-share, 6.8% stake in Nektar - Stock Titan
Thu, 16 Apr 2026
Nektar Therapeutics (NASDAQ:NKTR) Sets New 52-Week High - Time to Buy? - MarketBeat
Thu, 16 Apr 2026
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit - WBOC TV
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 29 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 60.9 (%) |
| Shares Short | 3,670 (K) |
| Shares Short P.Month | 3,490 (K) |
| EPS | -9.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.4 |
| Profit Margin | -297.1 % |
| Operating Margin | -87.6 % |
| Return on Assets (ttm) | -28 % |
| Return on Equity (ttm) | -218 % |
| Qtrly Rev. Growth | -25.3 % |
| Gross Profit (p.s.) | 1.92 |
| Sales Per Share | 1.92 |
| EBITDA (p.s.) | -4.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -209 (M) |
| Levered Free Cash Flow | -108 (M) |
| PE Ratio | -8.73 |
| PEG Ratio | 0 |
| Price to Book value | 19.24 |
| Price to Sales | 44.08 |
| Price to Cash Flow | -11.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|